Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Cormorant Asset Management, LP (CIK 1583977) reported $1.95B across 50 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: PRAX ($214.3M, 10.98%), BBOT ($136.2M, 6.98%), PBLS ($126.3M, 6.47%), RAPP ($110.7M, 5.67%), ERAS ($109.9M, 5.63%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PRAX | PRAXIS PRECISION MEDICINES I | $214.3M | 10.98% | 640,000 | Trimmed |
| 2 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $136.2M | 6.98% | 17.9M | Hold |
| 3 | PBLS | PARABILIS MEDICINES INC | $126.3M | 6.47% | 4.6M | New |
| 4 | RAPP | RAPPORT THERAPEUTICS INC | $110.7M | 5.67% | 2.7M | Trimmed |
| 5 | ERAS | ERASCA INC | $109.9M | 5.63% | 6.0M | Added |
| 6 | EWTX | EDGEWISE THERAPEUTICS INC | $102.0M | 5.23% | 2.5M | Trimmed |
| 7 | EYPT | EYEPOINT INC | $100.1M | 5.13% | 7.0M | Trimmed |
| 8 | ALMS | ALUMIS INC | $92.5M | 4.74% | 3.3M | Trimmed |
| 9 | ABVX | ABIVAX SA | $90.0M | 4.61% | 675,000 | Trimmed |
| 10 | DNTH | DIANTHUS THERAPEUTICS INC | $73.1M | 3.75% | 750,000 | Trimmed |
| 11 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $63.2M | 3.24% | 900,000 | Trimmed |
| 12 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $62.4M | 3.20% | 3.2M | Trimmed |
| 13 | BIOA | BIOAGE LABS INC | $58.6M | 3.00% | 2.4M | Trimmed |
| 14 | ORKA | ORUKA THERAPEUTICS INC | $50.8M | 2.60% | 533,340 | Hold |
| 15 | ANL | ADLAI NORTYE LTD | $45.7M | 2.34% | 4.0M | Added |
| 16 | BBIO | BRIDGEBIO PHARMA INC | $41.0M | 2.10% | 550,000 | Trimmed |
| 17 | TNGX | TANGO THERAPEUTICS INC | $40.6M | 2.08% | 1.3M | Trimmed |
| 18 | BHVN | BIOHAVEN LTD | $38.8M | 1.99% | 2.6M | Added |
| 19 | AGMB | AGOMAB THERAPEUTICS NV | $32.0M | 1.64% | 2.5M | Hold |
| 20 | MBX | MBX BIOSCIENCES INC | $30.4M | 1.56% | 550,000 | Trimmed |
| 21 | CLYM | CLIMB BIO INC | $27.5M | 1.41% | 2.1M | New |
| 22 | OLMA | OLEMA PHARMACEUTICALS INC | $26.9M | 1.38% | 2.1M | Trimmed |
| 23 | PHVS | PHARVARIS N V | $25.9M | 1.33% | 750,000 | Trimmed |
| 24 | DMRA | DAMORA THERAPEUTICS INC | $26.0M | 1.33% | 1.0M | Trimmed |
| 25 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $22.0M | 1.13% | 2.3M | Hold |
Source: SEC Form 13F filings · as of 2026-06-30